Diabetic Retinopathy

Worldwide increase in technologies for ophthalmic use is dramatic

Numerous studies will be completed during the next few years, and many new studies are being developed.

Study highlights role of demographic and socioeconomic characteristics in treatment

The hope is that future analyses would show more patients completing the pathway and a lower rate of missed appointments.

The development of a novel AI-based algorithm aims to improve risk prediction for diabetic eye disease.

Insights into the pathophysiology of diabetic macular edema are providing a basis for therapeutic interventions.

Multiple challenges remain for diabetic macular edema with unmet needs to improve treatment outcomes, speed of treatment benefit, and the duration of response.

Three risk-related baseline factors identified by this analysis may be associated with a potential need for injections.

A study including data from about 42,000 eyes found diabetic retinopathy (DR) severity is a risk factor for the progression of diabetic eye disease. Other findings support the idea that genetic factors influence the development of proliferative DR versus diabetic macular edema.

Study highlights the role of demographic and socioeconomic characteristics as contributors to disease- and treatment-related disparities among patients with diabetic macular edema.

A panel of experts in ophthalmology and optometry review the diagnosis and treatment of diabetic eye disease including emerging agents in the field.

Results support further research investigating transforming growth factor-β-Induced Gene Human Clone 30 (BIGH3).

The benefit is robust across a variety of demographics and baseline disease characteristics, according to data.

Study offers a real-world scenario of a very specific, but frequent and crucial aspect of the care of patients with diabetes, suggests clinician

Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy.

Results could provide a new preferred treatment paradigm for this population

Study explores correlations between functional and structural tests

The number of patients with retinal diseases is steadily increasing in the United States, according to a retrospective study presented during ARVO 2020.

Reductions in macular retinal nonperfusion after anti-VEGF treatment with aflibercept are correlated with improvements in BCVA and central retinal thickness in patients with DR/DME, according to a post-hoc analysis of the VISTA dataset, said Charles C. Wykoff, MD, PhD, during ARVO 2020.

Caesar Luo, MD, shares the take-away points from his ASRS presentation, and how the topics from his talk may be applied day to day in retinal practice.

Rates of anxiety and depression increased but were not necessarily tied to disease severity

A retrospective study found that in both patients with type 2 diabetes and non-diabetics, average central macular thickness was lower in Asians than Caucasians. Why is this significant for clinicians?

An analysis using a large commercial claims database found that almost 3% of patients developed severe diabetic eye disease within 5 years of being diagnosed with type 2 diabetes. Clinical and demographic risk factors were also identified.

A new analysis from the DRCR Network Protocol V showed that many patients with center-involved diabetic macular edema and good vision do not require treatment for visual acuity loss.